The World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD) has initiated the first steps in a long process that could lead to the rescheduling of medical marijuana under international law, and has committed to hold a special session to discuss medical marijuana. Over the next eighteen months, the committee has requested pre-reviews for cannabis plant matter, extracts and tinctures, delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and stereoisomers of THC. This pre-review is a preliminary analysis used to determine if a more in-depth critical review will be undertaken by the ECDD, and will represent the first new scientific guidance on marijuana to the United Nations since 1935, when cannabis was first classified as a Schedule I/IV substance by the Health Committee of the League of Nations. (Full story at medicaljane.com, and the WHO Committee Report)

CBD among reviews sought by WHO
Support HempToday with a donation
We appreciate our paying subscribers and strive to deliver the most complete, well-researched and comprehensive news, analysis and commentary about the hemp industries. If you’d like to further support us, click below to make a donation.